Q1 Earnings Estimate for AURA Issued By Leerink Partnrs

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Aura Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.49) per share for the quarter. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences' Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.47) EPS and Q4 2025 earnings at ($0.51) EPS.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02.

Several other analysts have also recently commented on the company. Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Scotiabank boosted their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a "sector outperform" rating in a research report on Friday, October 18th. Cowen reiterated a "buy" rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research boosted their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Finally, HC Wainwright restated a "buy" rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $23.00.

Aura Biosciences Stock Performance

Shares of AURA traded down $0.03 during trading hours on Friday, hitting $7.73. 136,443 shares of the stock were exchanged, compared to its average volume of 132,190. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The company has a market cap of $386.11 million, a price-to-earnings ratio of -4.47 and a beta of 0.29. The stock's 50-day moving average price is $8.14 and its two-hundred day moving average price is $8.84.

Insider Buying and Selling

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the sale, the insider now owns 151,693 shares of the company's stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,778 shares of company stock valued at $240,706. Corporate insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new position in Aura Biosciences during the 4th quarter worth approximately $87,000. AlphaQuest LLC purchased a new position in Aura Biosciences during the 4th quarter worth approximately $136,000. SG Americas Securities LLC purchased a new position in Aura Biosciences during the 3rd quarter worth approximately $169,000. Intech Investment Management LLC purchased a new position in Aura Biosciences during the 4th quarter worth approximately $172,000. Finally, American Century Companies Inc. grew its stake in Aura Biosciences by 33.9% during the 4th quarter. American Century Companies Inc. now owns 47,701 shares of the company's stock worth $392,000 after buying an additional 12,081 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company's stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.